Epidyolex® has gained approval from the European Commission for seizures associated with Lennox–Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
Ponesimod hits key endpoints in clinical trial for relapsing multiple sclerosis: industry news round-up
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
A recent transnational study has determined that daily use of high potency cannabis can increase the risk of developing psychotic disorder.
Research presented at SfN has provided insight into the neural risks and benefits of marijuana use, including development and Alzheimer’s disease.
Research presented at AAIC 2018 highlights the challenges and successes of both drug and non-drug treatments for non-cognitive symptoms experienced by individuals with Alzheimer’s disease.
Researchers reveal that post-traumatic stress disorder, anxiety and some types of inflammation may be alleviated by cannabis-like drugs.
GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Hannah Cock provides insight into the current data, controversies and pipelines for the use of cannabis-derived therapeutics in epilepsy.